Hepatocellular Carcinoma Immunotherapy
Top Cited Papers
- 27 January 2022
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 73 (1), 267-278
- https://doi.org/10.1146/annurev-med-042220-021121
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune checkpoint inhibitors (ICIs) demonstrated promising efficacy in early-phase trials, a finding that was not confirmed in phase III studies. The combination of atezolizumab (an anti-PD-L1 ICI) with bevacizumab (an anti-VEGF antibody) was approved as first-line therapy in 2020, however, with significant improvement in response rate, progression-free survival, and overall survival in comparison with the previous standard of care, sorafenib. Numerous ongoing clinical trials are assessing ICIs in combination with each other or with targeted agents, and also in earlier stages with local therapies. This review summarizes the latest concepts in the use of ICIs for the management of HCC. Expected final online publication date for the Annual Review of Medicine, Volume 73 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.Keywords
This publication has 52 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responsesNature Reviews Immunology, 2011
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- Chronically inflamed livers up-regulate expression of inhibitory B7 family membersJournal of Hepatology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- How the T Cell Receptor Sees Antigen—A Structural ViewCell, 2005
- Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive TumorsJournal of Clinical Oncology, 2004
- Randomized controlled trial of interferon treatment for advanced hepatocellular carcinomaJournal of Hepatology, 2000
- Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trialsJournal of Hepatology, 1999
- Patterns of recurrence after initial treatment in patients with small hepatocellular carcinomaJournal of Hepatology, 1997